Define the terms honestly, set a real floor, and stop pretending the pharmaceutical industry is the only voice in the room.
This week the FDA’s Pharmacy Compounding Advisory Committee sits down to decide the fate of seven peptides — BPC-157, TB-500, KPV, MOTS-C, Semax, Epitalon, and DSIP.
It is the most consequential moment this space has ever faced.
And the entire community I’ve spent the last two decades serving is holding its breath, waiting to see how the federal government decides to regulate a market that has grown far faster than the rules built to govern it.
I want that decision to go the right way. But let’s be clear about what the committee is actually voting on.
Whichever way it goes, that vote answers one narrow question: which of these compounds a licensed pharmacy may compound for a patient who walks in with a prescription.
That’s a real question, and it matters. But it’s not the whole picture.
Because the far bigger reality is that millions of people are already using these compounds today, right now, this morning. And that truth will not change based on a vote on a compounding list.
In other words, if the conversation stays that narrow, the people most exposed to real harm will be left exactly where they are.
So before the gavel comes down, I want to make the case for doing the right thing: define the terms honestly, build a safety floor for the real market that actually exists, and stop pretending the only people at the table are pharmacies and pharma.
Start With the Words, Because the Words Have Been Weaponized
Almost nobody in this debate can accurately define what a “research use only” peptide is.
But that one phrase is quietly shaping how the public and federal regulators think about quality.
Here’s what RUO really means.
It’s a labeling category that comes straight out of the framework for laboratory reagents and in-vitro diagnostics, written into FDA regulation.
A product that carries “For Research Use Only” is simply one the FDA hasn’t cleared or approved as a drug or a diagnostic.
That’s it.
It’s a statement about regulatory status and intended use and about what the seller is legally permitted to claim.
It is NOT a statement about how pure the material is or how well it was made.
Read that again, because the entire scare narrative collapses on it.
Over the years, “research use only” got deliberately reframed to imply a lower grade of product, reinforcing the idea a “research peptide” is something different, cheaper, or dirtier than the “real” version.
People now assume research peptides are an inferior class of material.
They absolutely are not.
A high-quality RUO peptide and a compounded peptide can come off the same synthesis, from the same manufacturer, at the same purity level.
The label reflects a legal lane but it does not reflect a level of quality or efficacy.
Once you understand that, most of the “gray market equals dangerous” story falls apart, and the actual danger finally comes into focus.
The Real Danger Is Already Here, and It’s Getting Worse
The threat was never the responsible provider publishing authentic third-party certificates of analysis.
The threat is the unregulated bottom of the supply chain, and it is deteriorating fast.
This year, news reporting has documented something that should stop everyone in this debate cold, no matter which side of the fence they’re on: Chinese manufacturers of fentanyl precursors have been pivoting into the peptide business, chasing a booming, barely-policed market after enforcement crushed their old one.
Independent testing has already turned up fentanyl in peptide products.
Buyers are flying blind, trusting vendor purity claims that often never test for contamination or sterility at all.
Analysts tracking the crypto behind this market watched it blow past $100 million, up more than 150% in a single quarter.
Let me say it plainly, because someone needs to: without standards, someone is going to die.
Not because peptides are inherently dangerous. I’ve run them on my own body for over 20 years and built my life’s work around them.
The danger comes from a market this size, growing like a rocket ship, with no floor under it.
This is an open invitation for the kind of contamination in a vial that will generate five alarm fire headlines.
But you don’t fix that by banning the compounds or making them harder to access. You fix it by building rules that separate the operators doing real safety work from the ones lacing products with fentanyl and other poisonous compounds.
This is the argument FOR regulation, not against it.
There Are 2 Populations, and the Framework Only Sees 1
Most of the current regulatory thinking is built around one type of person: the patient who walks into a clinic, asks a doctor for help, and needs a prescribing relationship and a high standard of care. That population is real, and it deserves exactly that level of attention.
Restoring compounds like BPC-157 and TB-500 to a clinician-supervised pathway would pull those people out of the danger zone, and I support it fully.
But it does not describe everyone.
There’s a second population, and it’s the one I know best: the self-directed optimizers, biohackers, competitive athletes, and health-driven pro-active adults who have read the studies, understand the risk profiles, and don’t require a prescription to make an informed decision about their own biology.
This group is not small, it isn’t going away, and it is not the reckless caricature regulators picture when they say “gray market.”
Many of these people have used these compounds responsibly for a decade or more.
My colleague Jeff Cohen, attorney and president of the American Peptide Association, put the underlying reality better than anyone:
“The wellness sector is entirely driven by consumers, not by clinicians, and not by pharmaceutical companies.”
He’s 100% right.
Pretending the market doesn’t exist doesn’t make it disappear; it just pushes it further into the dark.
And the responsible “RUO” providers serving that market are already doing a version of the exact safety work the formal system says is missing.
I AM talking about third-party purity testing, published certificates of analysis, sourcing traceable back to the manufacturer, and batch-level accountability.
That infrastructure got built without clinician gatekeepers, and it has been protecting this community while the formal system catches up.
Real-world outcomes tracked across thousands (perhaps millions) of users may not carry a p-value, but they are not nothing.
And any framework that pretends this population’s experience doesn’t count is building policy on half the evidence.
Follow the Money, and Follow Who’s in the Room
Here’s the part nobody with a lobbyist wants to be said out loud.
Pharma has the major seat at this table.
It always does.
When you have that seat, you get to shape the terms, such as which compounds get studied, which get vilified, and which manufacturing mandates get written in a way that just happens to protect your pricing.
Look at the incentive structure honestly.
As Jeff has pointed out in interviews with mainstream media, most of these peptides are naturally occurring compounds with no patent protection, which means no company can justify the cost of a massive clinical trial to prove what a lot of us already know.
No patent, no trial. No trial, no “evidence.”
No “evidence,” and suddenly the same compound gets called unproven.
This does not mean the science behind the compound fails. It means there is no profit incentive deciding what gets studied in the first place.
Meanwhile, the two GLP-1 giants, Eli Lilly and Novo Nordisk, have been busy suing compounding pharmacies, even though neither owns a single patent on the seven peptides in front of the committee this week.
Ask yourself who benefits when access gets squeezed and the only remaining option is a branded, patented, premium-priced product.
None of this is a conspiracy.
It’s just the reality of how these federal exercises work, and it’s worth being honest about.
The clinical pathway has representation in the form of compounding pharmacies and their clinicians.
Pharma has representation, in force.
But the legitimate operators who aren’t compounding pharmacies, and the millions of self-directed users they serve, have no seat at the table.
The framework is being built by the parties with high paid lobbyists, for the population without one.
The Fix
Alongside the clinician-supervised compounding pathway, regulators should build a second, parallel standard for the self-directed market.
A real regulatory floor, not a loophole, and not a ban dressed up as safety.
✅ Mandatory third-party testing.
✅ Published and authenticated certificates of analysis
✅ GMP-adjacent manufacturing requirements
✅ Clear, prominent education on what has and hasn’t been clinically established for any given compound.
That structure already separates the responsible operators from the ones cutting corners. It just must be recognized and enforced instead of ignored or maligned.
I’m not asking regulators to leave this community alone.
Not at all, I AM asking the opposite.
Look directly at the market that actually exists, define its terms honestly, and set standards that reduce harm for everyone already in it — including the people best equipped to use these compounds well.
The FDA has an opening this week to do something smarter than ban-versus-status-quo.
I AM asking the committee, and every regulator watching, to widen the room enough to let in everyone already standing in it, before the worst actors in this space make that decision for all of us.
This is about your right to your own biology. It always was.
Isn’t It Time You Became Fully Optimized To Live Leaner, Longer And Stronger?
Join my #1 online membership group, Fully Optimized Health to receive guidance from me and an elite group of more than 800 male and female biohackers (who all started out just like you)
And don’t forget to check out our other premium educational content dedicated to helping you fully optimize your health:
Quantum Peptides – the A-to-Z system for anyone (newbies & pros alike) desiring to master peptide use for the first time and forever.
Quantum Testosterone – the A-to-Z system for Men & Women to learn to optimize their hormones for explosive energy, lean muscle, and timeless vitality.
The Ultimate GLP-1 Video Masterclass – how to PROPERLY utilize the world’s most powerful weight loss drugs for enhanced fat loss and overall longevity.
The Modern Woman’s Peptide Course – a must-have resource for any woman seeking to become more feminine, sexier, leaner, and healthier through the use of peptides.
Life Enhanced – Unlock the secrets to TOTAL Mind-Body-Spirit Optimization as Hunter Williams and I teach you how to live at the tip of the spear.
30 Days 2 Shredz – Reprogram Your Mind and Body for Maximum Fat Loss in Minimum Time with our Optimized Fasting Protocol
Monica Campbell’s 3 Day PMF Video Training Program – Ignite unbreakable strength, sculpt lean muscle, and conquer workouts fearlessly with my wife Monica’s 3 Day Video training course.
Positive Muscle Failure Video Training Program – Learn how to lift weights correctly for maximum muscle in minimum time while building the physique of your dreams.
See you on the inside!
